Medicines

Find Medicines

Search 21,000+ medicines by brand, generic, indication, or drug class

Medicine Indications Drug Classes
    Showing all medicines (21591 total)

    Dubarel

    Aushokarist [Saraca Indica]
    Syrup Herbal Herbal and Nutraceuticals

    Indications

    Polycystic ovarian syndrome

    Indication detailsView
    Aushokarist is indicated in-
    • Dysfunctional uterine bleeding (DUB)
    • Secondary amenorrhea
    • Menorrhagia
    • Polycystic ovarian syndrome (PCOS)
    • Infertility.
    Therapeutic classView
    Herbal and Nutraceuticals
    PharmacologyView
    Saraca indica is one of the most popular remedy for menstrual disorders and female hormonal imbalances. The principal constituents of this tree are steroidal component and a calcium salt. The bark of Saraca indica contains an estrogenic compound called ergosterol. Other important chemical contents of Saraca indica are alkene esters, tannin, catachin, catechole and epicatechin.

    The herb has a stimulatory effect on the ovarian tissue, which may produce an estrogen-like activity that enhances ovulation and repair of the endometrium. It is a potent haemostyptic agent, also having stimulating effect on the muscular fiber of the uterus. It nourishes the blood, female reproductive organ and maintains healthy production of female hormones. It helps to regulate the menstrual cycle by controlling hypothalamic-pituitary-ovarian axis. Saraca indica, a proven PGH2 synthetase inhibitor, which effectively controls bleeding.

    Saraca indica is recommended in formulations for the management of pain with relation to uterus as anodynes. Beside these, the herb also has significant broad spectrum antibacterial activity. Mangifera indica is astringent, antiemetic and useful in haematocoagulatory disorders, uterine inflammation and diseases. It is an excellent vitalizer of the female genitourinary tract and tones it up to protect from number of disorders. It cures the menstrual pain and controls the uterine activity.

    It has also an antibacterial and antiviral properties. Cyperus rotundus is effective in the treatment of anemia and general weakness. Adhatoda vasica has antihemorrhagic activities and it is beneficial in dysfunctional uterine bleeding and an useful remedy in disorders of the uterus. The combined action of all these herbs help in ovulation, conception and proper implantation, which ultimately lead to normal pregnancy. The possible mechanism of combind ingredients of could be attributed to their synergistic action
    DosageView
    Above 12 years and Adult: 2-3 teaspoonfuls (10-15 ml) 2-3 times daily after meal for 3-6 months or as directed by the physician
    Side effectsView
    No health hazards or side effects are known in conjunction with the proper administration of designated therapeutic dosages.
    Pregnancy & lactationView
    Should not be used.
    StorageView
    Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

    Dudon

    Domperidone Maleate
    Oral Suspension 5 mg/5 ml Allopathic Motility Stimulants

    Indications

    Vomiting

    Indication detailsView
    Dyspeptic symptom complex, often associated with delayed gastric emptying, gastroesophageal reflux and esophagitis:
    • Epigastric sense of fullness, feeling of abdominal distension, upper abdominal pain
    • Eructation, flatulence, early satiety
    • Nausea and vomiting
    • Heartburn with or without regurgitations of gastric contents in the mouth
    • Non-ulcer dyspepsia
    Acute nausea and vomiting of the functional, organic, infectious, dietetic origin or induced by radiotherapy or drug therapy or induced in migraine.

    Parkinson's disease    : In dopamine-agonist induced nausea and vomiting.

    Radiological studies    : Speeding barium transit in follow-through radiological studies.
    Therapeutic classView
    Motility Stimulants, Motility stimulants/Dopamine antagonist, Prokinetic drugs
    PharmacologyView
    Domperidone is a dopamine antagonist that principally blocks the dopamine receptors located in the ChemoreceptorTrigger Zone (CTZ) and stomach. Its gastroprokinetic action is based on its blocking effect of dopamine receptors that have an influence on the motility of the gastrointestinal tract. Due to its weak penetration across the blood-brain barrier, Domperidone has almost no effect on the dopaminergic receptors in the brain, therefore, excluding psychotropic and neurologic side effects. Domperidone restores normal motility and tone of the upper gastrointestinal tract, facilitates gastric emptying, enhances antral and duodenal peristalsis and regulates contraction of the pylorus. Domperidone also increases esophageal peristalsis and lower esophageal sphincter pressure, and thus prevents regurgitation of gastric content.
    DosageView
    Domperidone should be taken 15-30 minutes before meals and, if necessary, before retiring.

    The usual recommended oral dose of Domperidone is as follows:
    • Adults: 10-20 mg (1-2 tablet or 10-20 ml suspension), every 6-8 hours daily. The maximum dose of Domperidone is 80 mg daily.
    • Children: 2-4 ml suspension/10 kg body weight or 0.4-0.8 ml paediatric drops/10 kg body weight, every 6-8 hours daily.
    In dyspeptic symptom:
    • Adults: 10-20 mg (1-2 tablet or 10-20 ml suspension), every 6-8 hours daily.
    • Children: 0.2-0.4 mg/kg (2-4 ml suspension/10 kg or 0.4-0.8 ml paediatric drops/10 kg) body weight, every 6-8 hours daily.
    In acute and sub-acute conditions (mainly in acute nausea and vomiting):
    • Adults: 20 mg (2 tablets or 20 ml suspension), every 6-8 hours daily
    • Children: 0.2-0.4 mg/kg (2-4 ml suspension/10 kg or 0.4-0.8 ml paediatric drops/10 kg) body weight, every 6-8 hours daily. (In acute nausea and vomiting maximum period of treatment is 12 weeks).
    By rectum in suppositories:
    • Adults (including elderly): 30-60 mg every 4-8 hours.
    • Children: The maximum daily dose rectally in children's is 30 mg for those weighting 10 to 25 kg. The dose may be divided throughout day if necessary.
    • The maximum period of treatment is 12 weeks.
    Side effectsView
    Domperidone may produce hyperprolactinemia (1.3%).This may result in galactorrhea, breast enlargement, and soreness and reduced libido. Dry mouth (1%), thirst, headache (1.2%), nervousness, drowsiness (0.4%), diarrhea (0.2%), skin rash and itching (0.1%) may occur during treatment with domperidone. Extra-pyramidal reactions are seen in 0.05% of patients in clinical studies.
    ContraindicationsView
    Domperidone is contraindicated to patients having known hypersensitivity to this drug and in the case of neonates. Domperidone should not be used whenever gastrointestinal stimulation might be dangerous i.e., gastrointestinal hemorrhage, mechanical obstruction or perforation. Also contraindicated in patients with prolactin releasing pituitary tumor (prolactinoma).
    PrecautionsView
    Domperidone should be used with absolute caution in the case of children because there may be an increased risk of extra-pyramidal reactions in young children because of an incompletely developed blood-brain barrier. Since domperidone is highly metabolized in liver, it should be used with caution in patient with hepatic impairment.
    InteractionsView
    Domperidone may reduce the risk of hypoprolactemic effect of bromocriptine. The action of Domperidone on Gl function may be antagonized by antimuscarinics and opoid analgesics. Care should be exercised when domperidone is administered in combination with MAO (monoamine oxidase) inhibitors.
    Pregnancy & lactationView
    The safety of domperidone has not been proven and it is therefore not recommended during pregnancy. Animal studies have not demonstrated the teratogenic effect in the fetus. Domperidone may precipitate galactorrhea and improve post-natal lactation. It is secreted in breast milk but in very small quantities insufficient to be considered harmful.
    Overdose effectsView
    There are no reported cases of overdose.
    StorageView
    Store below 30°C, Protected from light & moisture. Keep out of children's reach.

    Dudon

    Domperidone Maleate
    Tablet 10 mg Allopathic Motility Stimulants

    Indications

    Vomiting

    Indication detailsView
    Dyspeptic symptom complex, often associated with delayed gastric emptying, gastroesophageal reflux and esophagitis:
    • Epigastric sense of fullness, feeling of abdominal distension, upper abdominal pain
    • Eructation, flatulence, early satiety
    • Nausea and vomiting
    • Heartburn with or without regurgitations of gastric contents in the mouth
    • Non-ulcer dyspepsia
    Acute nausea and vomiting of the functional, organic, infectious, dietetic origin or induced by radiotherapy or drug therapy or induced in migraine.

    Parkinson's disease    : In dopamine-agonist induced nausea and vomiting.

    Radiological studies    : Speeding barium transit in follow-through radiological studies.
    Therapeutic classView
    Motility Stimulants, Motility stimulants/Dopamine antagonist, Prokinetic drugs
    PharmacologyView
    Domperidone is a dopamine antagonist that principally blocks the dopamine receptors located in the ChemoreceptorTrigger Zone (CTZ) and stomach. Its gastroprokinetic action is based on its blocking effect of dopamine receptors that have an influence on the motility of the gastrointestinal tract. Due to its weak penetration across the blood-brain barrier, Domperidone has almost no effect on the dopaminergic receptors in the brain, therefore, excluding psychotropic and neurologic side effects. Domperidone restores normal motility and tone of the upper gastrointestinal tract, facilitates gastric emptying, enhances antral and duodenal peristalsis and regulates contraction of the pylorus. Domperidone also increases esophageal peristalsis and lower esophageal sphincter pressure, and thus prevents regurgitation of gastric content.
    DosageView
    Domperidone should be taken 15-30 minutes before meals and, if necessary, before retiring.

    The usual recommended oral dose of Domperidone is as follows:
    • Adults: 10-20 mg (1-2 tablet or 10-20 ml suspension), every 6-8 hours daily. The maximum dose of Domperidone is 80 mg daily.
    • Children: 2-4 ml suspension/10 kg body weight or 0.4-0.8 ml paediatric drops/10 kg body weight, every 6-8 hours daily.
    In dyspeptic symptom:
    • Adults: 10-20 mg (1-2 tablet or 10-20 ml suspension), every 6-8 hours daily.
    • Children: 0.2-0.4 mg/kg (2-4 ml suspension/10 kg or 0.4-0.8 ml paediatric drops/10 kg) body weight, every 6-8 hours daily.
    In acute and sub-acute conditions (mainly in acute nausea and vomiting):
    • Adults: 20 mg (2 tablets or 20 ml suspension), every 6-8 hours daily
    • Children: 0.2-0.4 mg/kg (2-4 ml suspension/10 kg or 0.4-0.8 ml paediatric drops/10 kg) body weight, every 6-8 hours daily. (In acute nausea and vomiting maximum period of treatment is 12 weeks).
    By rectum in suppositories:
    • Adults (including elderly): 30-60 mg every 4-8 hours.
    • Children: The maximum daily dose rectally in children's is 30 mg for those weighting 10 to 25 kg. The dose may be divided throughout day if necessary.
    • The maximum period of treatment is 12 weeks.
    Side effectsView
    Domperidone may produce hyperprolactinemia (1.3%).This may result in galactorrhea, breast enlargement, and soreness and reduced libido. Dry mouth (1%), thirst, headache (1.2%), nervousness, drowsiness (0.4%), diarrhea (0.2%), skin rash and itching (0.1%) may occur during treatment with domperidone. Extra-pyramidal reactions are seen in 0.05% of patients in clinical studies.
    ContraindicationsView
    Domperidone is contraindicated to patients having known hypersensitivity to this drug and in the case of neonates. Domperidone should not be used whenever gastrointestinal stimulation might be dangerous i.e., gastrointestinal hemorrhage, mechanical obstruction or perforation. Also contraindicated in patients with prolactin releasing pituitary tumor (prolactinoma).
    PrecautionsView
    Domperidone should be used with absolute caution in the case of children because there may be an increased risk of extra-pyramidal reactions in young children because of an incompletely developed blood-brain barrier. Since domperidone is highly metabolized in liver, it should be used with caution in patient with hepatic impairment.
    InteractionsView
    Domperidone may reduce the risk of hypoprolactemic effect of bromocriptine. The action of Domperidone on Gl function may be antagonized by antimuscarinics and opoid analgesics. Care should be exercised when domperidone is administered in combination with MAO (monoamine oxidase) inhibitors.
    Pregnancy & lactationView
    The safety of domperidone has not been proven and it is therefore not recommended during pregnancy. Animal studies have not demonstrated the teratogenic effect in the fetus. Domperidone may precipitate galactorrhea and improve post-natal lactation. It is secreted in breast milk but in very small quantities insufficient to be considered harmful.
    Overdose effectsView
    There are no reported cases of overdose.
    StorageView
    Store below 30°C, Protected from light & moisture. Keep out of children's reach.

    Duet

    Paracetamol + Caffeine
    Tablet 500 mg+65 mg Allopathic Non opioid analgesics

    Indications

    Toothache

    Indication detailsView
    The is indicated in the following condition-
    • Headache
    • Migraine
    • Toothache
    • Neuralgia
    • Feverishness
    • Period pain
    • Sore throat
    • Backache
    • Help to reduce the temperature
    • Aches and pain of colds and flu
    Therapeutic classView
    Non opioid analgesics
    PharmacologyView
    This is a combination of Paracetamol and Caffeine. Paracetamol has analgesic and antipyretic properties with weak anti-inflammatory activity. Caffeine is an alkaloid which is a theophylline-like xanthine derivative. By intermolecular association with Paracetamol, Caffeine increases the solubility and transmembrane permeation of Paracetamol. In addition, Caffeine increases the pain threshold and tolerance of pain. Caffeine has also an intrinsic power to raise vessel tone in the brain, which provides another benefit to treat migraine and headache.
    DosageView
    Adult dose: 1-2 tablets every 4-6 hours. Maximum dose: 8 tablets daily.
    Child dose: Not recommended for children below 12 years.
    Side effectsView
    Side effects of paracetamol are usually mild, though haematological reactions including thrombocytopenia, leukopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. Pancreatitis, skin rashes, and other allergic reactions occur occasionally.
    ContraindicationsView
    Paracetamol is contraindicated in patients with severe renal function impairment and hepatic disease (Viral Hepatitis). Known hypersensitivity to paracetamol or caffeine.
    PrecautionsView
    Paracetamol & Caffeine should be given cautiously in the following cases: In patients with hepatic or renal failure, in patients taking other hepatotoxic medication. Prolonged use of the drug without consulting a physician should be avoided.
    InteractionsView
    May reduce serum levels with anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins with prolonged use. Accelerated absorption with metoclopramide and domperidone. May increase serum levels with probenecid. May increase serum levels of chloramphenicol. May reduce absorption with colestyramine within 1 hr of admin. May cause severe hypothermia with phenothiazine.
    Pregnancy & lactationView
    Pregnant mothers should consult with doctors before taking Paracetamol & Caffeine. Paracetamol & Caffeine can be taken whilst breast feeding.
    Overdose effectsView
    Symptoms of Paracetamol overdose in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 40 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur.
    StorageView
    Store in a cool and dry place, protect from light and moisture.Keep all medicines out of the reach of the children.

    Dugal

    Ranitidine Hydrochloride
    Tablet 150 mg Allopathic H2 receptor antagonist

    Indications

    Zollinger-Ellison syndrome

    Indication detailsView
    Ranitidine is indicated in:
    • Treatment of active duodenal ulcer
    • Benign gastric ulcer
    • Treatment & prevention of ulcer associated with non-steroidal anti-inflammatory agent
    • Post operative stress ulcer.
    • Zollinger-Ellison Syndrome.
    • Gastroesophageal reflux disease (GERD).
    • Gastro-intestinal haemorrhage from stress ulcer in seriously ill patient.
    • Recurrent haemorrhage in patients with bleeding peptic ulcer.
    • Before general anesthesia in patient considered to be at risk of acid aspiration particulary obstetric patients.
    Therapeutic classView
    H2 receptor antagonist
    PharmacologyView
    Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
    DosageView

    Ranitidine Tablet & Syrup:

    Duodenal and gastric ulcer: The usual dosage is 150 mg twice daily taken in the morning and evening or 300 mg as a single daily dose at night for 4 to 8 weeks.

    Reflux oesophagitis: 150 mg twice daily or 300 mg at bed time for up to 8 weeks.

    Zollinger Ellison syndrome: 150 mg 3 times daily and increased if necessary up to 6 g daily in divided doses. Dosage should be continued as long as clinically indicated.

    Episodic dyspepsia: 150 mg twice daily or 300 mg at bed time for up to 6 weeks.

    Maintenance: 150 mg at night for preventing recurrences.

    Child (peptic ulcer): 2-4 mg/kg twice daily, maximum 300 mg daily.


    Ranitidine IV injection & IV Infusion:

    Ranitidine injection may be given either as a slow (over a period of at least two minutes) intravenous injection of 50 mg, after dilution to a volume of 20 ml per 50 mg dose, which may be repeated every six to eight hours; or as an intermittent intravenous infusion at a rate of 25 mg per hour for two hours; the infusion may be repeated at six to eight hour intervals; or as an intramuscular injection of 50 mg (2 ml) every six to eight hours. In the prophylaxis of haemorrhage from stress ulceration in seriously ill patients or the prophylaxis of recurrent haemorrhage in patients bleeding from peptic ulceration, parenteral administration may be continued until oral feeding commences.

    In the prophylaxis of upper gastrointestinal haemorrhage from stress ulceration in seriously ill patient sapriming dose of 50 mg as low as intravenous injection followed by a continuous intravenous infusion of 0.125-0.250 mg/kg/hour may be preferred. In patients considered to be at risk of developing aspiration syndrome Ranitidine injection 50 mg may be given intramuscularly or by slow intravenous injection 45 to 60 minutes before induction of general anaesthesia.

    Children: The recommended oral dose for the treatment of peptic ulcer in children is 2 mg/kg to 4 mg/kg twice daily to a maximum of 300 mg ranitidine per day. Safety and effectiveness of Ranitidine injection have not been established in case of children.
    Side effectsView
    Ranitidine is well tolerated and side effects are usually uncommon. Altered bowel habit, dizziness, rash, tiredness, reversible confusional states, headache, decreased blood counts, muscle or joint pain have rarely been reported.
    ContraindicationsView
    Patients hypersensitive to Ranitidine
    PrecautionsView
    Ranitidine should be given in reduced dosage to patients with impaired renal and hepatic function.
    InteractionsView
    Delayed absorption and increased peak serum concentration with propantheline bromide. Ranitidine minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam and propanolol. May alter absorption of pH-dependent drugs (e.g. ketoconazole, midazolam, glipizide). May reduce bioavailability with antacids.
    Pregnancy & lactationView
    Pregnancy: Ranitidine crosses the placenta. But there is no evidence of impaired fertility or harm to the foetus due to Ranitidine. Like other drugs, Ranitidine should only be used during pregnancy if considered essential.

    Lactation: Ranitidine is excreted in human breast milk. Caution should be exercised when the drug is administered to a nursing mother.
    Pediatric usageView
    Use in elderly patients: In clinical trial the ulcer healing rates have been found similar in patients age 65 and over with those in younger patients. Additionally, there was no difference in the incidence of adverse effects.
    Overdose effectsView
    Ranitidine is very specific in action and accordingly no particular problems are expected following overdosage with the drug. Symptomatic and supportive therapy should be given as appropriate. If required, the drug may be removed from the plasma by haemodiaiysis.
    ReconstitutionView
    Slow IV inj: Ranitidine 50 mg diluted to a concentration ≤2.5 mg/mL (e.g. total of 20 mL) with NaCl 0.9% inj or dextrose 5% or 10%, lactated Ringer's, Na bicarbonate 5% soln.

    Intermittent slow IV infusion: Ranitidine 50 mg diluted to a concentration ≤0.5 mg/mL (e.g. total of 100 mL) of dextrose 5% inj or NaCl 0.9%, lactated Ringer's, Na bicarbonate 5% soln.

    Continuous IV infusion:     Ranitidine 150 mg diluted in 250 mL of dextrose 5% inj or NaCl 0.9%, lactated Ringer's, Na bicarbonate 5% soln.

    Patients with Zollinger-Ellison syndrome or other hypersecretory conditions: Ranitidine should be diluted to a concentration ≤2.5 mg/mL with dextrose 5% or NaCl 0.9%, lactated Ringer's, Na bicarbonate 5% soln.
    StorageView
    Store in a cool and dry place. protect from light.

    Dukoral

    Oral Cholera Vaccine
    Oral Suspension 3 ml/vial Allopathic Vaccines, Anti-sera & Immunoglobulin

    Indications

    Cholera

    Indication detailsView
    Oral Cholera Vaccine is indicated for active immunization against Vibrio cholerae. The vaccine can be administered to anyone above the age of 1 year. Data for the safety and efficacy of the vaccine in infants (less than 1 year of age) is not available. The earliest onset of protection can be expected 7-10 days after the completion of the primary series of the vaccine. Efficacy against Vibrio cholerae serogroup O139 was not demonstrated.
    Therapeutic classView
    Vaccines, Anti-sera & Immunoglobulin
    DosageView
    The recommended dose of the vaccine (1.5 ml) is to be administered orally. The primary immunization schedule consists of two doses given at an interval of at least two weeks. Cholera vaccine should not be administered parenterally (intramuscular, subcutaneous or intravenously). The vaccine is only recommended for oral administration.

    Method of administration: The vaccine is presented as a suspension. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient. The vaccine administration may be optionally followed by water to facilitate ingestion, if needed. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient. The vaccine should not be administered parenterally (intramuscular, subcutaneous or intravenously). The vaccine is only recommended for oral administration.
    Side effectsView
    The following adverse events are known to occur with cholera vaccine use. Acute gastroenteritis, diarrhea, fever, vomiting, abdominal pain, itching, rash, nausea, weakness, cough, vertigo, dryness of mouth, oral ulcer (rare), sore throat (rare) and yellowing of urine (rare). It has been observed that the incidence of adverse events is less after the second dose as compared to the first.
    ContraindicationsView
    Cholera vaccine should not be administered to subjects with either known hypersensitivity to any component of vaccine, or having shown signs of hypersensitivity after previous administration of the vaccine. Formaldehyde is used during the manufacturing process and trace amounts may be present in the final product. Caution should be taken in subjects with known hypersensitivity to formaldehyde. CVV V.N. 02 TM As with other vaccines, immunization with the cholera vaccine should be delayed in the presence of any acute illness, including acute gastrointestinal illness or acute febrile illness. A minor illness such as mild upper respiratory tract infection is not a reason to postpone immunization
    PrecautionsView
    Vaccination should be provided by a review of the medical history (especilly with regard to previous vaccination & possible occurrence of the undesirable events) and a clinical examination. As with any vaccine immunization with the cholera vaccine may not protect 100% susceptible individuals. This vaccine is also not a substitute for therapy in case of individuals suspected to be suffering from cholera or showing signs and symptoms of an acute episode of gastro intestinal disease or acute watery diarrhea. Immunocompromised persons (subsequent to a disease or immunosuppressive therapy) may not obtain the expected immune response after vaccination with the cholera vaccine. If possible, in the opinion of the medical practitioner, due consideration should be given to postpone vaccination until after the completion of the immunosuppressive treatment. As with all vaccines, appropriate medical treatment should always be available in case of a rare event of anaphylactic reactions following the administration of the vaccine. For this reason, it is recommended that the vaccinee should remain under medical supervision for at least 30 minutes after vaccination.
    Pregnancy & lactationView
    No specific clinical studies have been performed to evaluate the safety and immunogenicity of cholera vaccine in pregnant women and for the fetus. However, administration of cholera vaccine to pregnant women and nursing mother may be considered after careful evaluation of the benefits and risks in case of a medical emergency or an epidemic.
    StorageView
    Keep out of the reach and sight of children. Store at +2 ºC to +8 ºC. Transportation should also be at +2 ºC to +8 ºC. Do not freeze. Discard vaccine if frozen. Protect from light.

    Dulac

    Lactulose
    Oral Solution 3.35 gm/5 ml Allopathic Osmotic purgatives

    Indications

    Osmotic laxative

    Indication detailsView
    Constipation (Chronic Constipation): In every case of chronic constipation, initial treatment should consist of a diet rich in fiber (vegetables, salads, fruits etc.) a generous amount of liquids and much physical exercise. Lactulose is only to be taken when these measures prove insufficient.

    Intestinal flora disturbances:
    • In damaged to intestinal flora (e.g. following long-term antibiotic treatment)
    • gall bladder diseases
    • intestinal diseases ( Colitis, Diverticulosis, Megacolon)
    Increased blood ammonia levels (hyper ammoniemia in hepatopathy, portal-systemic encephalopathy)
    Therapeutic classView
    Osmotic purgatives
    PharmacologyView
    Lactulose is a synthetic disaccharide. Lactulose is metabolized in the colon by the saccharolytic bacteria, producing low molecular weight organic acids (mainly lactic acid), which lowers the pH of the colon contents, promote the retention of water by an osmotic effect; thus increasing peristaltic activity. Lactulose is minimally absorbed; therefore, the pharmacokinetics of the absorbed material are not relevant to the principal therapeutic action.
    DosageView
    In constipation ( chronic constipation):
    • Adults: Initially 3-6 tea-spoons daily, In long-term therapy 1½-6 tea-spoons daily
    • Children up to 14 years: Initially 3 tea-spoons daily, In long-term therapy 1-2 tea-spoons daily
    • Infants and toddlers: Initially 1-2 tea-spoons daily, In long-term therapy 1 tea-spoon daily
    In damaged intestinal flora:
    • Adults: 1-2 tea-spoons daily
    • Children: 1 tea-spoon daily
    For reduction of blood ammonia level:
    • Hyper-ammoniemia in hepatopathy: a maximum of 18-30 tea-spoons daily.
    • In portal systemic encephalopathy: hourly doses of 6-9 tea-spoons of Lactulose solution may be used to induce the rapid laxation. When the laxative effect has been achieved, the dose may then be reduced.
    Side effectsView
    Occasionally flatulence, cramp and abdominal discomfort can occur at the beginning of treatment; this is rapidly eliminated by reducing the dose. Overdose can result in diarrhoea. In abuse, loss of electrolytes (primarily potassium).
    ContraindicationsView
    Hypersensitivity to either galactose and or lactose; galactose-free diet, gastro-cardial symptom complex, suspected intestinal obstruction.
    PrecautionsView
    Lactulose should be administered with care to patients who are intolerant to lactulose. The dose used in the treatment of (pre) coma hepaticum is usually much higher and may need to be taken into consideration for diabetics.
    InteractionsView
    There is no significant drug interactions with lactulose. The glycosidic effect of cardiac glycosides can be intensified by potassium deficiency in abuse.
    Pregnancy & lactationView
    US FDA Pregnancy Category of Lactulose is B. Studies show that Lactulose has no adverse effects. Decisions regarding use during pregnancy and lactation must be made by registered physician.
    Overdose effectsView
    There have been no reports of accidental overdosage. In the event of acute overdosage it is expected that diarrhoea and abdominal cramps would be the major symptoms.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Dulamet

    Mometasone Furoate + Formoterol Fumarate
    Inhaler (100 mcg+5 mcg)/puff Allopathic
    Indication detailsView
    This inhaler is used for asthma as follows:
    • This inhaler is a prescription medicine used to control symptoms of asthma and prevent symptoms such as wheezing in people 12 years of age and older.
    • This inhaler contains Formoterol which is a Long Acting β2 Agonist (LABA). When it is used alone increase the risk of hospitalizations and death from asthma problems. This contains an ICS and a LABA. When an ICS and LABA are used together, there is not a significant increased risk in hospitalizations and death from asthma problems.
    • This inhaler is not for adults and adolescent patients with asthma who are well controlled with an asthma control medicine, such as a low to medium dose ICS medicine. This inhaler is for adults and adolescent patients with asthma who need both an ICS and LABA medicine.
    PharmacologyView
    Mometasone furoate is an inhaled corticosteroid- ICS for short. Inhaled corticosteroids help to decrease inflammation in the lungs. Infammation in the lungs can lead to breathing problems. Formoterol fumarate is a long-acting beta-2 agonist- LABA for short. LABA medicines help the muscles around the airways of the lungs stay relaxed to prevent asthma symptoms, such as wheezing, cough, chest tightness, and shortness of breath. These symptoms can happen when the muscles around the airways tighten. This makes it hard to breathe.
    DosageView
    Adult and adolescent patients aged 12 Years and older: Dosage is either 2 inhalations twice daily of 200 HFA inhaler or 100 HFA inhaler. When choosing the starting dosage strength of this inhaler, consider the patients' disease severity, based on their previous asthma therapy, including the inhaled corticosteroid dosage, as well as the patients' current control of asthma symptoms and risk of future exacerbation. The maximum recommended dosage is two inhalations of 200 HFA inhaler twice daily (maximum daily dosage 800 mcg/20 mcg). After each dose of 2 puffs, rinse your mouth with water. Spit out the water. Do not swallow it. This will help to prevent thrush in your mouth or throat.
    AdministrationView
    • Remove the cap and shake the inhaler vigorously before each use.
    • Holding the inhaler well away from your mouth, breathe out gently (but not fully).
    • Place the mouthpiece in your mouth and close your lips around it.
    • After starting to breathe in slowly and deeply through your mouth, press the metal canister firmly to release the powder, and continue to breathe in.
    • Remove the inhaler from your mouth and hold your breath for 10 seconds, or as long as it is comfortable, then breathe out slowly.
    • If you take a second inhalation, you should wait for at least one minute before repeating steps 2, 3 and 4. After use replace the cap on the mouthpiece.
    • Check your technique in front of a mirror from time to time, if you see a white mist during the inhalation you may not have closed your lips properly around mouthpiece, or you may not be breathing in as you press the can. This indicates failure of technique. If this happens, repeat the procedure from step 2 carefully.
    • It is very important that the plastic mouthpiece is to be cleaned regularly to prevent build-up of spare powder. Remove the metal canister and wash the plastic mouthpiece in warm water at least twice a week. Leave to dry in a warm place overnight. No harm will come with from washing the mouthpiece every day. For further assistance / information please consult with your physician.
    Side effectsView
    The most common side effects of this combination include inflammation of the nose and throat, inflammation of the sinuses, headache, flu, and upper respiratory infection. Other less common side-effects include: serious allergic reactions, thrush in the mouth & throat, reduces adrenal function, increase in wheezing, lower bone mineral density in osteoporosis patient, slowed growth in children, glaucoma, blurred vision & hypokalemia.
    ContraindicationsView
    This combination is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. This combination is contraindicated in patients with known hypersensitivity to Mometasone Furoate, Formoterol Fumarate, or any of the ingredients in this combination.
    InteractionsView
    • Strong cytochrome P450 3A4 inhibitors: Use with caution. May cause increased systemic corticosteroid effects.
    • Adrenergic agents: Use with caution. Additional adrenergic drugs may potentiate sympathetic effects
    • Xanthine derivatives and diuretics: Use with caution. May potentiate ECG changes and/or hypokalemia.
    • MAO inhibitors, tricyclic antidepressants, macrolides, and drugs that prolong QTc interval: Use with extreme caution. May potentiate effect on the cardiovascular system.
    • Beta-blockers: Use with caution and only when medically necessary. May decrease effectiveness and produce severe bronchospasm.
    • Halogenated hydrocarbons: There is an elevated risk of arrhythmias in patients receiving concomitant anesthesia with halogenated hydrocarbons.
    Pregnancy & lactationView
    The use of this combination during pregnancy and lactation should be restricted to those patients in whom the benefits clearly outweigh the risk.
    Pediatric usageView
    Hepatic/Renal Impairment: There are no data regarding the specific use of this combination in patients with hepatic or renal impairment.

    Geriatrics: The pharmacokinetics of this combination have not been specifically studied in the elderly population.
    StorageView
    Keep out of the reach of children. Store below 30°C protected from direct sunlight and heat. Keep away from contact of eyes. The container should not be punctured, broken or burnt even when apparently empty.

    Dulamet

    Mometasone Furoate + Formoterol Fumarate
    Inhaler (200 mcg+5 mcg)/puff Allopathic
    Indication detailsView
    This inhaler is used for asthma as follows:
    • This inhaler is a prescription medicine used to control symptoms of asthma and prevent symptoms such as wheezing in people 12 years of age and older.
    • This inhaler contains Formoterol which is a Long Acting β2 Agonist (LABA). When it is used alone increase the risk of hospitalizations and death from asthma problems. This contains an ICS and a LABA. When an ICS and LABA are used together, there is not a significant increased risk in hospitalizations and death from asthma problems.
    • This inhaler is not for adults and adolescent patients with asthma who are well controlled with an asthma control medicine, such as a low to medium dose ICS medicine. This inhaler is for adults and adolescent patients with asthma who need both an ICS and LABA medicine.
    PharmacologyView
    Mometasone furoate is an inhaled corticosteroid- ICS for short. Inhaled corticosteroids help to decrease inflammation in the lungs. Infammation in the lungs can lead to breathing problems. Formoterol fumarate is a long-acting beta-2 agonist- LABA for short. LABA medicines help the muscles around the airways of the lungs stay relaxed to prevent asthma symptoms, such as wheezing, cough, chest tightness, and shortness of breath. These symptoms can happen when the muscles around the airways tighten. This makes it hard to breathe.
    DosageView
    Adult and adolescent patients aged 12 Years and older: Dosage is either 2 inhalations twice daily of 200 HFA inhaler or 100 HFA inhaler. When choosing the starting dosage strength of this inhaler, consider the patients' disease severity, based on their previous asthma therapy, including the inhaled corticosteroid dosage, as well as the patients' current control of asthma symptoms and risk of future exacerbation. The maximum recommended dosage is two inhalations of 200 HFA inhaler twice daily (maximum daily dosage 800 mcg/20 mcg). After each dose of 2 puffs, rinse your mouth with water. Spit out the water. Do not swallow it. This will help to prevent thrush in your mouth or throat.
    AdministrationView
    • Remove the cap and shake the inhaler vigorously before each use.
    • Holding the inhaler well away from your mouth, breathe out gently (but not fully).
    • Place the mouthpiece in your mouth and close your lips around it.
    • After starting to breathe in slowly and deeply through your mouth, press the metal canister firmly to release the powder, and continue to breathe in.
    • Remove the inhaler from your mouth and hold your breath for 10 seconds, or as long as it is comfortable, then breathe out slowly.
    • If you take a second inhalation, you should wait for at least one minute before repeating steps 2, 3 and 4. After use replace the cap on the mouthpiece.
    • Check your technique in front of a mirror from time to time, if you see a white mist during the inhalation you may not have closed your lips properly around mouthpiece, or you may not be breathing in as you press the can. This indicates failure of technique. If this happens, repeat the procedure from step 2 carefully.
    • It is very important that the plastic mouthpiece is to be cleaned regularly to prevent build-up of spare powder. Remove the metal canister and wash the plastic mouthpiece in warm water at least twice a week. Leave to dry in a warm place overnight. No harm will come with from washing the mouthpiece every day. For further assistance / information please consult with your physician.
    Side effectsView
    The most common side effects of this combination include inflammation of the nose and throat, inflammation of the sinuses, headache, flu, and upper respiratory infection. Other less common side-effects include: serious allergic reactions, thrush in the mouth & throat, reduces adrenal function, increase in wheezing, lower bone mineral density in osteoporosis patient, slowed growth in children, glaucoma, blurred vision & hypokalemia.
    ContraindicationsView
    This combination is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. This combination is contraindicated in patients with known hypersensitivity to Mometasone Furoate, Formoterol Fumarate, or any of the ingredients in this combination.
    InteractionsView
    • Strong cytochrome P450 3A4 inhibitors: Use with caution. May cause increased systemic corticosteroid effects.
    • Adrenergic agents: Use with caution. Additional adrenergic drugs may potentiate sympathetic effects
    • Xanthine derivatives and diuretics: Use with caution. May potentiate ECG changes and/or hypokalemia.
    • MAO inhibitors, tricyclic antidepressants, macrolides, and drugs that prolong QTc interval: Use with extreme caution. May potentiate effect on the cardiovascular system.
    • Beta-blockers: Use with caution and only when medically necessary. May decrease effectiveness and produce severe bronchospasm.
    • Halogenated hydrocarbons: There is an elevated risk of arrhythmias in patients receiving concomitant anesthesia with halogenated hydrocarbons.
    Pregnancy & lactationView
    The use of this combination during pregnancy and lactation should be restricted to those patients in whom the benefits clearly outweigh the risk.
    Pediatric usageView
    Hepatic/Renal Impairment: There are no data regarding the specific use of this combination in patients with hepatic or renal impairment.

    Geriatrics: The pharmacokinetics of this combination have not been specifically studied in the elderly population.
    StorageView
    Keep out of the reach of children. Store below 30°C protected from direct sunlight and heat. Keep away from contact of eyes. The container should not be punctured, broken or burnt even when apparently empty.

    Dulong

    Dapoxetine Hydrochloride
    Tablet 30 mg Allopathic Drugs for Erectile Dysfunction

    Indications

    Premature ejaculation

    Indication detailsView
    Indicated for the treatment of premature ejaculation (PE) in men 18 to 64 years of age, who have all of the following:
    • Persistent or recurrent ejaculation with minimal sexual stimulation before, on or shortly after penetration and before the patient wishes.
    • Marked personal distress or interpersonal difficulty as a consequence of PE and poor control over ejaculation.
    Therapeutic classView
    Drugs for Erectile Dysfunction
    PharmacologyView
    The mechanism of action is thought to be related to inhibition of neuronal reuptake of serotonin and subsequent potentiation of serotonin activity. The central ejaculatory neural circuit comprises spinal and cerebral areas that form a highly interconnected network. The sympathetic, parasympathetic, and somatic spinal centers, under the influence of sensory genital and cerebral stimuli integrated and processed at the spinal cord level, act in synergy to command physiologic events occurring during ejaculation. Experimental evidence indicates that serotonin (5-HT), throughout brain descending pathways, exerts an inhibitory role on ejaculation. To date, three 5-HT receptor subtypes 5-HT(1A), 5-HT(1B), and 5-HT(2C) have been postulated to mediate 5-HT's modulating activity on ejaculation.
    DosageView
    Adult (18 to 64 years of age): The recommended starting dose for all patients is 30 mg, taken as needed approximately 1 to 3 hours prior to sexual activity. If the effect of 30 mg is insufficient and the side effects are acceptable, the dose may be increased to the maximum recommended dose of 60 mg. The maximum recommended dosing frequency is one dose every 24 hours.
    Side effectsView
    Dizziness, Headache, Somnolence, Tremor, Blurred vision, Tinnitus, Sinus congestion, Nausea, Diarrhea, Abdominal pain, Dry mouth, Fatigue, Insomnia, Hypertension.
    ContraindicationsView
    • Patients with known hypersensitivity to Dapoxetine Hydrochloride.
    • Patients with significant pathological cardiac conditions such as heart failure (NYHA class II-IV), conduction abnormalities (second or third degree AV block or sick sinus syndrome) not treated with a permanent pacemaker, significant ischemic heart disease of significant valvular disease.
    • Concomitant treatment with monoamine oxidase inhibitors (MAOIs), thioridazine. Similarly, MAOIs or thioridazine should not be administered within 7 days after Dapoxetine has been discontinued.
    • Concomitant treatment with serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs) or other medicinal/herbal products with serotonergic effects or within 14 days of discontinuing treatment with these medicinal/herbal products.
    PrecautionsView
    Patient with bleeding disorders, epilepsy, susceptibility to angle-closure glaucoma or raised intraocular pressure. Not intended for use in women. Known CYP2D6 poor metabolisers.
    InteractionsView
    CNS active medicinal products: The use of Dapoxetine in combination with CNS active medicinal products has not been systematically evaluated in patients with premature ejaculation. Consequently, caution is advised if the concomitant administration of Dapoxetine and such medicinal products is required.

    PDE5 inhibitors: Tadalafil did not affect the pharmacokinetics of Dapoxetine. Sildenafil caused slight changes in Dapoxetine pharmacokinetics, which are not expected to be clinically significant. However, Dapoxetine should be prescribed with caution in patients who use PDE5 inhibitors due to possible reduced orthostatic tolerance.

    Tamsulosin: Concomitant administration of single or multiple doses of 30 mg or 60 mg Dapoxetine to patients receiving daily doses of Tamsulosin did not result in changes in the pharmacokinetics of Tamsulosin. However, Dapoxetine should be prescribed with caution in patients who use alpha adrenergic receptor antagonists due to possible reduced orthostatic tolerance.

    Warfarin: There are no data evaluating the effect of chronic use of Warfarin with Dapoxetine; therefore, caution is advised when Dapoxetine is used in patients taking Warfarin chronically.

    Ethanol: Concomitant use of alcohol and Dapoxetine could increase the chance or severity of adverse reactions such as dizziness, drowsiness, slow reflexes, or altered judgment. Combining alcohol with Dapoxetine may increase these alcohol-related effects and may also enhance neurocardiogenic adverse events such as syncope, thereby increasing the risk of accidental injury; therefore, patients should be advised to avoid alcohol while taking Dapoxetine.
    Pregnancy & lactationView
    Dapoxetine is not indicated for use by women. It is not known either dapoxetine or its metabolites are excreted through human breast milk.
    Overdose effectsView
    There were no unexpected adverse events in a clinical pharmacology study of Dapoxetine with daily doses up to 240 mg. In general, symptoms of overdose with SSRIs include serotonin-mediated adverse reactions such as somnolence, gastrointestinal disturbances such as nausea and vomiting, tachycardia, tremor, agitation and dizziness. In cases of overdose, standard supportive measures should be adopted as required.
    StorageView
    Store below 30°C. Protect from light and moisture. Keep out of reach of children

    Dulox

    Duloxetine Hydrochloride
    Tablet (Delayed Release) 30 mg Allopathic Serotonin-norepinephrine reuptake inhibitor (SNRI)

    Indications

    Urinary incontinence

    Indication detailsView
    Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for-
    • Major Depressive Disorder (MDD)
    • Generalized Anxiety Disorder (GAD)
    • Diabetic Peripheral Neuropathic Pain (DPNP)
    • Fibromyalgia and
    • Chronic Musculoskeletal Pain.
    Therapeutic classView
    Serotonin-norepinephrine reuptake inhibitor (SNRI)
    PharmacologyView
    Duloxetine Hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) for oral administration. Duloxetine is a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors in vitro. Duloxetine does not inhibit monoamine oxidase (MAO). Orally administered Duloxetine hydrochloride is well absorbed. Elimination of Duloxetine is mainly through hepatic metabolism.
    DosageView
    Major Depressive Disorder (MDD)-
    • Starting Dose: 40 mg/day to 60 mg/day
    • Target Dose: Acute: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or as 30 mg twice daily); Maintenance: 60 mg/day
    • Maximum Dose: 120 mg/day
    Generalized Anxiety Disorder (GAD)-
    • Starting Dose: 60 mg/day
    • Target Dose: 60 mg/day (once daily)
    • Maximum Dose: 120 mg/day
    Diabetic Peripheral Neuropathic Pain (DPNP)-
    • Starting Dose: 60 mg/day
    • Target Dose: 60 mg/day (once daily)
    • Maximum Dose: 60 mg/day
    Fibromyalgia-
    • Starting Dose: 30 mg/day
    • Target Dose: 60 mg/day (once daily)
    • Maximum Dose: 60 mg/day
    Chronic Musculoskeletal Pain-
    • Starting Dose: 30 mg/day
    • Target Dose: 60 mg/day (once daily)
    • Maximum Dose: 60 mg/day
    Some patients may benefit from starting at 30 mg once daily. There is no evidence that doses greater than 60 mg/day confers an additional benefit, while some adverse reactions were observed to be dose-dependent. A gradual dose reduction is recommended to avoid discontinuation symptoms.
    Side effectsView
    The most commonly observed adverse events in Duloxetine hydrochloride treated patients were nausea, dizziness, dry mouth, constipation, decreased appetite, fatigue, somnolence, increased sweating, hyperhidrosis and asthenia. It may slightly increase blood pressure. No clinically significant differences were observed for QT, PR, and QRS intervals between Duloxetine-treated and placebo-treated patients.
    ContraindicationsView
    Duloxetine is contraindicated in patients with a known hypersensitivity to this drug or any of the inactive ingredients. Duloxetine is not approved for use in treating bipolar depression. Duloxetine should not be prescribed to patients with substantial alcohol use or evidence of chronic liver disease. In clinical trials, Duloxetine was associated with an increased risk of mydriasis; therefore, it should be used cautiously in patients with controlled narrow-angle glaucoma.
    PrecautionsView
    All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes. Blood pressure should be measured prior to initiating treatment and periodically measured throughout treatment. Patients should be cautioned about the risk of bleeding associated with the concomitant use of Duloxetine and NSAIDs, aspirin, or other drugs that affect coagulation. Duloxetine should be used cautiously in patients with a history of mania. Duloxetine should be prescribed with care in patients with a history of a seizure disorder.
    InteractionsView
    Both CYP1A2 and CYP2D6 isozymes are responsible for Duloxetine metabolism. When Duloxetine was co-administered with fluvoxamine, a potent CYP1A2 inhibitor, the AUC, Cmax and t of Duloxetine was increased. Other drugs that inhibit CYP1A2 metabolism include cimetidine and quinolone antimicrobials such as ciprofloxacin and enoxacin would be expected to have similar effects and these combinations should be avoided. Because CYP2D6 is involved in Duloxetine metabolism, concomitant use of Duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of Duloxetine.
    Pregnancy & lactationView
    Pregnancy: Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women; therefore, Duloxetine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    Labor and Delivery: The effect of Duloxetine on labor and delivery in humans is unknown. Duloxetine should be used during labor and delivery only if the potential benefit justifies the potential risk to the fetus.

    Lactation: It is unknown whether or not Duloxetine and/or it's metabolites are excreted into human milk, but nursing while on Duloxetine is not recommended
    Pediatric usageView
    Use in the pediatric population: Safety and efficacy in pediatric patients have not been established
    Overdose effectsView
    There is limited clinical experience with Duloxetine overdose in humans. There is no specific antidote to Duloxetine. In case of acute overdose, treatment should consist of those general measures employed in the management of overdose with any drug. An adequate airway, oxygenation, and ventilation should be assured, and cardiac rhythm and vital signs should be monitored. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients. Activated charcoal may be useful in limiting the absorption of Duloxetine from the gastrointestinal tract.
    StorageView
    Do not store above 30°C. Keep away from light and out of the reach of children.

    Dulox

    Duloxetine Hydrochloride
    Tablet (Delayed Release) 20 mg Allopathic Serotonin-norepinephrine reuptake inhibitor (SNRI)

    Indications

    Urinary incontinence

    Indication detailsView
    Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for-
    • Major Depressive Disorder (MDD)
    • Generalized Anxiety Disorder (GAD)
    • Diabetic Peripheral Neuropathic Pain (DPNP)
    • Fibromyalgia and
    • Chronic Musculoskeletal Pain.
    Therapeutic classView
    Serotonin-norepinephrine reuptake inhibitor (SNRI)
    PharmacologyView
    Duloxetine Hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) for oral administration. Duloxetine is a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors in vitro. Duloxetine does not inhibit monoamine oxidase (MAO). Orally administered Duloxetine hydrochloride is well absorbed. Elimination of Duloxetine is mainly through hepatic metabolism.
    DosageView
    Major Depressive Disorder (MDD)-
    • Starting Dose: 40 mg/day to 60 mg/day
    • Target Dose: Acute: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or as 30 mg twice daily); Maintenance: 60 mg/day
    • Maximum Dose: 120 mg/day
    Generalized Anxiety Disorder (GAD)-
    • Starting Dose: 60 mg/day
    • Target Dose: 60 mg/day (once daily)
    • Maximum Dose: 120 mg/day
    Diabetic Peripheral Neuropathic Pain (DPNP)-
    • Starting Dose: 60 mg/day
    • Target Dose: 60 mg/day (once daily)
    • Maximum Dose: 60 mg/day
    Fibromyalgia-
    • Starting Dose: 30 mg/day
    • Target Dose: 60 mg/day (once daily)
    • Maximum Dose: 60 mg/day
    Chronic Musculoskeletal Pain-
    • Starting Dose: 30 mg/day
    • Target Dose: 60 mg/day (once daily)
    • Maximum Dose: 60 mg/day
    Some patients may benefit from starting at 30 mg once daily. There is no evidence that doses greater than 60 mg/day confers an additional benefit, while some adverse reactions were observed to be dose-dependent. A gradual dose reduction is recommended to avoid discontinuation symptoms.
    Side effectsView
    The most commonly observed adverse events in Duloxetine hydrochloride treated patients were nausea, dizziness, dry mouth, constipation, decreased appetite, fatigue, somnolence, increased sweating, hyperhidrosis and asthenia. It may slightly increase blood pressure. No clinically significant differences were observed for QT, PR, and QRS intervals between Duloxetine-treated and placebo-treated patients.
    ContraindicationsView
    Duloxetine is contraindicated in patients with a known hypersensitivity to this drug or any of the inactive ingredients. Duloxetine is not approved for use in treating bipolar depression. Duloxetine should not be prescribed to patients with substantial alcohol use or evidence of chronic liver disease. In clinical trials, Duloxetine was associated with an increased risk of mydriasis; therefore, it should be used cautiously in patients with controlled narrow-angle glaucoma.
    PrecautionsView
    All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes. Blood pressure should be measured prior to initiating treatment and periodically measured throughout treatment. Patients should be cautioned about the risk of bleeding associated with the concomitant use of Duloxetine and NSAIDs, aspirin, or other drugs that affect coagulation. Duloxetine should be used cautiously in patients with a history of mania. Duloxetine should be prescribed with care in patients with a history of a seizure disorder.
    InteractionsView
    Both CYP1A2 and CYP2D6 isozymes are responsible for Duloxetine metabolism. When Duloxetine was co-administered with fluvoxamine, a potent CYP1A2 inhibitor, the AUC, Cmax and t of Duloxetine was increased. Other drugs that inhibit CYP1A2 metabolism include cimetidine and quinolone antimicrobials such as ciprofloxacin and enoxacin would be expected to have similar effects and these combinations should be avoided. Because CYP2D6 is involved in Duloxetine metabolism, concomitant use of Duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of Duloxetine.
    Pregnancy & lactationView
    Pregnancy: Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women; therefore, Duloxetine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    Labor and Delivery: The effect of Duloxetine on labor and delivery in humans is unknown. Duloxetine should be used during labor and delivery only if the potential benefit justifies the potential risk to the fetus.

    Lactation: It is unknown whether or not Duloxetine and/or it's metabolites are excreted into human milk, but nursing while on Duloxetine is not recommended
    Pediatric usageView
    Use in the pediatric population: Safety and efficacy in pediatric patients have not been established
    Overdose effectsView
    There is limited clinical experience with Duloxetine overdose in humans. There is no specific antidote to Duloxetine. In case of acute overdose, treatment should consist of those general measures employed in the management of overdose with any drug. An adequate airway, oxygenation, and ventilation should be assured, and cardiac rhythm and vital signs should be monitored. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients. Activated charcoal may be useful in limiting the absorption of Duloxetine from the gastrointestinal tract.
    StorageView
    Do not store above 30°C. Keep away from light and out of the reach of children.

    Duloxen

    Duloxetine Hydrochloride
    Tablet (Delayed Release) 20 mg Allopathic Serotonin-norepinephrine reuptake inhibitor (SNRI)

    Indications

    Urinary incontinence

    Indication detailsView
    Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for-
    • Major Depressive Disorder (MDD)
    • Generalized Anxiety Disorder (GAD)
    • Diabetic Peripheral Neuropathic Pain (DPNP)
    • Fibromyalgia and
    • Chronic Musculoskeletal Pain.
    Therapeutic classView
    Serotonin-norepinephrine reuptake inhibitor (SNRI)
    PharmacologyView
    Duloxetine Hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) for oral administration. Duloxetine is a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors in vitro. Duloxetine does not inhibit monoamine oxidase (MAO). Orally administered Duloxetine hydrochloride is well absorbed. Elimination of Duloxetine is mainly through hepatic metabolism.
    DosageView
    Major Depressive Disorder (MDD)-
    • Starting Dose: 40 mg/day to 60 mg/day
    • Target Dose: Acute: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or as 30 mg twice daily); Maintenance: 60 mg/day
    • Maximum Dose: 120 mg/day
    Generalized Anxiety Disorder (GAD)-
    • Starting Dose: 60 mg/day
    • Target Dose: 60 mg/day (once daily)
    • Maximum Dose: 120 mg/day
    Diabetic Peripheral Neuropathic Pain (DPNP)-
    • Starting Dose: 60 mg/day
    • Target Dose: 60 mg/day (once daily)
    • Maximum Dose: 60 mg/day
    Fibromyalgia-
    • Starting Dose: 30 mg/day
    • Target Dose: 60 mg/day (once daily)
    • Maximum Dose: 60 mg/day
    Chronic Musculoskeletal Pain-
    • Starting Dose: 30 mg/day
    • Target Dose: 60 mg/day (once daily)
    • Maximum Dose: 60 mg/day
    Some patients may benefit from starting at 30 mg once daily. There is no evidence that doses greater than 60 mg/day confers an additional benefit, while some adverse reactions were observed to be dose-dependent. A gradual dose reduction is recommended to avoid discontinuation symptoms.
    Side effectsView
    The most commonly observed adverse events in Duloxetine hydrochloride treated patients were nausea, dizziness, dry mouth, constipation, decreased appetite, fatigue, somnolence, increased sweating, hyperhidrosis and asthenia. It may slightly increase blood pressure. No clinically significant differences were observed for QT, PR, and QRS intervals between Duloxetine-treated and placebo-treated patients.
    ContraindicationsView
    Duloxetine is contraindicated in patients with a known hypersensitivity to this drug or any of the inactive ingredients. Duloxetine is not approved for use in treating bipolar depression. Duloxetine should not be prescribed to patients with substantial alcohol use or evidence of chronic liver disease. In clinical trials, Duloxetine was associated with an increased risk of mydriasis; therefore, it should be used cautiously in patients with controlled narrow-angle glaucoma.
    PrecautionsView
    All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes. Blood pressure should be measured prior to initiating treatment and periodically measured throughout treatment. Patients should be cautioned about the risk of bleeding associated with the concomitant use of Duloxetine and NSAIDs, aspirin, or other drugs that affect coagulation. Duloxetine should be used cautiously in patients with a history of mania. Duloxetine should be prescribed with care in patients with a history of a seizure disorder.
    InteractionsView
    Both CYP1A2 and CYP2D6 isozymes are responsible for Duloxetine metabolism. When Duloxetine was co-administered with fluvoxamine, a potent CYP1A2 inhibitor, the AUC, Cmax and t of Duloxetine was increased. Other drugs that inhibit CYP1A2 metabolism include cimetidine and quinolone antimicrobials such as ciprofloxacin and enoxacin would be expected to have similar effects and these combinations should be avoided. Because CYP2D6 is involved in Duloxetine metabolism, concomitant use of Duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of Duloxetine.
    Pregnancy & lactationView
    Pregnancy: Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women; therefore, Duloxetine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    Labor and Delivery: The effect of Duloxetine on labor and delivery in humans is unknown. Duloxetine should be used during labor and delivery only if the potential benefit justifies the potential risk to the fetus.

    Lactation: It is unknown whether or not Duloxetine and/or it's metabolites are excreted into human milk, but nursing while on Duloxetine is not recommended
    Pediatric usageView
    Use in the pediatric population: Safety and efficacy in pediatric patients have not been established
    Overdose effectsView
    There is limited clinical experience with Duloxetine overdose in humans. There is no specific antidote to Duloxetine. In case of acute overdose, treatment should consist of those general measures employed in the management of overdose with any drug. An adequate airway, oxygenation, and ventilation should be assured, and cardiac rhythm and vital signs should be monitored. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients. Activated charcoal may be useful in limiting the absorption of Duloxetine from the gastrointestinal tract.
    StorageView
    Do not store above 30°C. Keep away from light and out of the reach of children.

    Duloxen

    Duloxetine Hydrochloride
    Tablet (Delayed Release) 30 mg Allopathic Serotonin-norepinephrine reuptake inhibitor (SNRI)

    Indications

    Urinary incontinence

    Indication detailsView
    Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for-
    • Major Depressive Disorder (MDD)
    • Generalized Anxiety Disorder (GAD)
    • Diabetic Peripheral Neuropathic Pain (DPNP)
    • Fibromyalgia and
    • Chronic Musculoskeletal Pain.
    Therapeutic classView
    Serotonin-norepinephrine reuptake inhibitor (SNRI)
    PharmacologyView
    Duloxetine Hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) for oral administration. Duloxetine is a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors in vitro. Duloxetine does not inhibit monoamine oxidase (MAO). Orally administered Duloxetine hydrochloride is well absorbed. Elimination of Duloxetine is mainly through hepatic metabolism.
    DosageView
    Major Depressive Disorder (MDD)-
    • Starting Dose: 40 mg/day to 60 mg/day
    • Target Dose: Acute: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or as 30 mg twice daily); Maintenance: 60 mg/day
    • Maximum Dose: 120 mg/day
    Generalized Anxiety Disorder (GAD)-
    • Starting Dose: 60 mg/day
    • Target Dose: 60 mg/day (once daily)
    • Maximum Dose: 120 mg/day
    Diabetic Peripheral Neuropathic Pain (DPNP)-
    • Starting Dose: 60 mg/day
    • Target Dose: 60 mg/day (once daily)
    • Maximum Dose: 60 mg/day
    Fibromyalgia-
    • Starting Dose: 30 mg/day
    • Target Dose: 60 mg/day (once daily)
    • Maximum Dose: 60 mg/day
    Chronic Musculoskeletal Pain-
    • Starting Dose: 30 mg/day
    • Target Dose: 60 mg/day (once daily)
    • Maximum Dose: 60 mg/day
    Some patients may benefit from starting at 30 mg once daily. There is no evidence that doses greater than 60 mg/day confers an additional benefit, while some adverse reactions were observed to be dose-dependent. A gradual dose reduction is recommended to avoid discontinuation symptoms.
    Side effectsView
    The most commonly observed adverse events in Duloxetine hydrochloride treated patients were nausea, dizziness, dry mouth, constipation, decreased appetite, fatigue, somnolence, increased sweating, hyperhidrosis and asthenia. It may slightly increase blood pressure. No clinically significant differences were observed for QT, PR, and QRS intervals between Duloxetine-treated and placebo-treated patients.
    ContraindicationsView
    Duloxetine is contraindicated in patients with a known hypersensitivity to this drug or any of the inactive ingredients. Duloxetine is not approved for use in treating bipolar depression. Duloxetine should not be prescribed to patients with substantial alcohol use or evidence of chronic liver disease. In clinical trials, Duloxetine was associated with an increased risk of mydriasis; therefore, it should be used cautiously in patients with controlled narrow-angle glaucoma.
    PrecautionsView
    All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes. Blood pressure should be measured prior to initiating treatment and periodically measured throughout treatment. Patients should be cautioned about the risk of bleeding associated with the concomitant use of Duloxetine and NSAIDs, aspirin, or other drugs that affect coagulation. Duloxetine should be used cautiously in patients with a history of mania. Duloxetine should be prescribed with care in patients with a history of a seizure disorder.
    InteractionsView
    Both CYP1A2 and CYP2D6 isozymes are responsible for Duloxetine metabolism. When Duloxetine was co-administered with fluvoxamine, a potent CYP1A2 inhibitor, the AUC, Cmax and t of Duloxetine was increased. Other drugs that inhibit CYP1A2 metabolism include cimetidine and quinolone antimicrobials such as ciprofloxacin and enoxacin would be expected to have similar effects and these combinations should be avoided. Because CYP2D6 is involved in Duloxetine metabolism, concomitant use of Duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of Duloxetine.
    Pregnancy & lactationView
    Pregnancy: Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women; therefore, Duloxetine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    Labor and Delivery: The effect of Duloxetine on labor and delivery in humans is unknown. Duloxetine should be used during labor and delivery only if the potential benefit justifies the potential risk to the fetus.

    Lactation: It is unknown whether or not Duloxetine and/or it's metabolites are excreted into human milk, but nursing while on Duloxetine is not recommended
    Pediatric usageView
    Use in the pediatric population: Safety and efficacy in pediatric patients have not been established
    Overdose effectsView
    There is limited clinical experience with Duloxetine overdose in humans. There is no specific antidote to Duloxetine. In case of acute overdose, treatment should consist of those general measures employed in the management of overdose with any drug. An adequate airway, oxygenation, and ventilation should be assured, and cardiac rhythm and vital signs should be monitored. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients. Activated charcoal may be useful in limiting the absorption of Duloxetine from the gastrointestinal tract.
    StorageView
    Do not store above 30°C. Keep away from light and out of the reach of children.

    Duloxen

    Duloxetine Hydrochloride
    Tablet (Delayed Release) 60 mg Allopathic Serotonin-norepinephrine reuptake inhibitor (SNRI)

    Indications

    Urinary incontinence

    Indication detailsView
    Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for-
    • Major Depressive Disorder (MDD)
    • Generalized Anxiety Disorder (GAD)
    • Diabetic Peripheral Neuropathic Pain (DPNP)
    • Fibromyalgia and
    • Chronic Musculoskeletal Pain.
    Therapeutic classView
    Serotonin-norepinephrine reuptake inhibitor (SNRI)
    PharmacologyView
    Duloxetine Hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) for oral administration. Duloxetine is a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors in vitro. Duloxetine does not inhibit monoamine oxidase (MAO). Orally administered Duloxetine hydrochloride is well absorbed. Elimination of Duloxetine is mainly through hepatic metabolism.
    DosageView
    Major Depressive Disorder (MDD)-
    • Starting Dose: 40 mg/day to 60 mg/day
    • Target Dose: Acute: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or as 30 mg twice daily); Maintenance: 60 mg/day
    • Maximum Dose: 120 mg/day
    Generalized Anxiety Disorder (GAD)-
    • Starting Dose: 60 mg/day
    • Target Dose: 60 mg/day (once daily)
    • Maximum Dose: 120 mg/day
    Diabetic Peripheral Neuropathic Pain (DPNP)-
    • Starting Dose: 60 mg/day
    • Target Dose: 60 mg/day (once daily)
    • Maximum Dose: 60 mg/day
    Fibromyalgia-
    • Starting Dose: 30 mg/day
    • Target Dose: 60 mg/day (once daily)
    • Maximum Dose: 60 mg/day
    Chronic Musculoskeletal Pain-
    • Starting Dose: 30 mg/day
    • Target Dose: 60 mg/day (once daily)
    • Maximum Dose: 60 mg/day
    Some patients may benefit from starting at 30 mg once daily. There is no evidence that doses greater than 60 mg/day confers an additional benefit, while some adverse reactions were observed to be dose-dependent. A gradual dose reduction is recommended to avoid discontinuation symptoms.
    Side effectsView
    The most commonly observed adverse events in Duloxetine hydrochloride treated patients were nausea, dizziness, dry mouth, constipation, decreased appetite, fatigue, somnolence, increased sweating, hyperhidrosis and asthenia. It may slightly increase blood pressure. No clinically significant differences were observed for QT, PR, and QRS intervals between Duloxetine-treated and placebo-treated patients.
    ContraindicationsView
    Duloxetine is contraindicated in patients with a known hypersensitivity to this drug or any of the inactive ingredients. Duloxetine is not approved for use in treating bipolar depression. Duloxetine should not be prescribed to patients with substantial alcohol use or evidence of chronic liver disease. In clinical trials, Duloxetine was associated with an increased risk of mydriasis; therefore, it should be used cautiously in patients with controlled narrow-angle glaucoma.
    PrecautionsView
    All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes. Blood pressure should be measured prior to initiating treatment and periodically measured throughout treatment. Patients should be cautioned about the risk of bleeding associated with the concomitant use of Duloxetine and NSAIDs, aspirin, or other drugs that affect coagulation. Duloxetine should be used cautiously in patients with a history of mania. Duloxetine should be prescribed with care in patients with a history of a seizure disorder.
    InteractionsView
    Both CYP1A2 and CYP2D6 isozymes are responsible for Duloxetine metabolism. When Duloxetine was co-administered with fluvoxamine, a potent CYP1A2 inhibitor, the AUC, Cmax and t of Duloxetine was increased. Other drugs that inhibit CYP1A2 metabolism include cimetidine and quinolone antimicrobials such as ciprofloxacin and enoxacin would be expected to have similar effects and these combinations should be avoided. Because CYP2D6 is involved in Duloxetine metabolism, concomitant use of Duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of Duloxetine.
    Pregnancy & lactationView
    Pregnancy: Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women; therefore, Duloxetine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    Labor and Delivery: The effect of Duloxetine on labor and delivery in humans is unknown. Duloxetine should be used during labor and delivery only if the potential benefit justifies the potential risk to the fetus.

    Lactation: It is unknown whether or not Duloxetine and/or it's metabolites are excreted into human milk, but nursing while on Duloxetine is not recommended
    Pediatric usageView
    Use in the pediatric population: Safety and efficacy in pediatric patients have not been established
    Overdose effectsView
    There is limited clinical experience with Duloxetine overdose in humans. There is no specific antidote to Duloxetine. In case of acute overdose, treatment should consist of those general measures employed in the management of overdose with any drug. An adequate airway, oxygenation, and ventilation should be assured, and cardiac rhythm and vital signs should be monitored. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients. Activated charcoal may be useful in limiting the absorption of Duloxetine from the gastrointestinal tract.
    StorageView
    Do not store above 30°C. Keep away from light and out of the reach of children.

    Dumaflox

    Ciprofloxacin
    Tablet 250 mg Allopathic Anti-diarrhoeal Antimicrobial drugs

    Indications

    Urinary tract infection

    Indication detailsView
    Ciprofloxacin is indicated for the treatment of Respiratory Tract Infections,Urinary tract infections, Pelvic Inflammatory Diseases, Infectious Diarrhea (Shigella dysenteriae, Vibrio cholera), Typhoid fever, Intra-abdominal infections, Prostatitis, Skin and Soft Tissue Infections, Bone and Joint Infections, Gonorrhea, Neutropenic patients with fever due to bacterial infection, Meningitis, Surgical prophylaxis.
    Therapeutic classView
    4-Quinolone preparations, Anti-diarrhoeal Antimicrobial drugs
    PharmacologyView
    Ciprofloxacin is a synthetic fluoroquinolone. It has bactericidal activity against a wide range of gram-positive and gram-negative organisms. It inhibits bacterial DNA synthesis by binding with the bacterial enzyme-DNA gyrase and topoisomerase IV which are responsible for DNA supercoiling.
    DosageView
    Tablet: Adult:
    • Respiratory Tract Infections: 500 to 750 mg twice daily (7 to 14 days)
    • Urinary tract infections: 250 to 750 mg twice daily (3 to 10 days)
    • Pelvic Inflammatory Diseases: 500 to 750 mg twice daily (14 days)
    • Infectious Diarrhea (Shigella dysenteriae, Vibrio cholera): 500 mg twice daily (1 to 5 days)
    • Typhoid fever: 500 mg twice daily (7 days)
    • Intra-abdominal infections: 500 to 750 mg twice daily (5 to 14 days)
    • Prostatitis: 500 to 750 mg twice daily (2 to 6 weeks)
    • Skin and Soft Tissue Infections: 500 to 750 mg twice daily (7 to 14 days)
    • Bone and Joint Infections: 500 to 750 mg twice daily (max. 3 months)
    • Gonorrhea: 500 mg as a single dose
    • Neutropenic patients with fever due to bacterial infection: 500 to 750 mg twice daily co-administered with appropriate antibacterials.
    • Meningitis: 500 mg as a single dose.
    • Surgical prophylaxis: 500 mg as a single dose, 60 minutes before the procedure.
    Suspension: Pediatric: 10-20 mg/kg (max. 750 mg) twice daily (10 to 21 days). The duration of therapy depends on the type and severity of the infection.

    Extended-release tablet: In uncomplicated urinary tract infection (acute cystitis), the recommended dose of extended-release tablet is 1000 mg tablet once daily for three days.

    For IV infusion:
    • Urinary Tract Infection: Mild to Moderate: 200 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 12 hourly for 7-14 days
    • Lower Respiratory Tract infection: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days
    • Nosocomial Pneumonia: Mild/Moderate/Severe: 400 mg 8 hourly for 10-14 days
    • Skin and Skin Structure: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days
    • Bone and Joint Infection: Mild to Moderate: 400 mg 12 hourly for more than 4-6 weeks; Severe/Complicated: 400 mg 8 hourly for more than 4-6weeks
    • Intraabdominal (Acute abdomen): Complicated: 400 mg 12 hourly for 7-14 days
    • Acute Sinusitis: Mild/Moderate: 400 mg 12 hourly for 10 days
    • Chronic Bacterial Prostatitis: Mild/Moderate: 400 mg 12 hourly for 28 Days.
    AdministrationView
    Instruction for the use of Ciprofloxacin IV infusion-
    • Check the bag for minute leaks by squeezing the inner bag firmly. If leaks are found, or if seal is not intact, discard the solution.
    • Do not use if the solution is cloudy or a precipitate is present.
    • Do not use flexible bags in series connections.
    • Close flow control clamp of administration set.
    • Remove cover from port at bottom of bag.
    • Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated.
    • Suspend bag from hanger.
    • Squeeze and release drip chamber to establish proper fluid level in chamber during infusion of Ciprofloxacin IV infusion.
    • Open flow control clamp to expel air from set.Close clamp.
    • Regulate rate of administration with flow control clamp
    Duration of treatment: The duration of treatment depends upon the severity of infection, clinical response and bacteriological findings. For acute infections the usual treatment period is 5 to 10 days. Generally treatment should be continued for 3 days after the signs and symptoms of the infection have been disappeared.
    Side effectsView
    Side effects include- nausea and other gastrointestinal disturbances, headache, dizziness, joint pain and skin rashes.
    ContraindicationsView
    It is contraindicated in patients who have known hypersensitivity to Ciprofloxacin or other quinolones.
    PrecautionsView
    Patients receiving Ciprofloxacin should be instructed to drink fluids liberally. It should be used with caution in patients with suspected or known CNS disorders such as epilepsy or other factors which predispose to seizures and convulsion. Avoid in patients with known QT prolongation, hypokalemia.
    InteractionsView
    Concurrent administration of Ciprofloxacin should be avoided with Magnesium or Aluminum containing antacids or sucralfate or with other products containing Calcium, Iron or Zinc. These products may be taken two hours after or six hours before Ciprofloxacin. Ciprofloxacin should not be taken concurrently with milk or other dairy products, since absorption of Ciprofloxacin may be significantly reduced. Dietary calcium is a part of a meal, however, does not significantly affect the absorption of Ciprofloxacin.
    Pregnancy & lactationView
    There are no adequate and well-controlled studies in pregnant women. Ciprofloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus and mother. Ciprofloxacin is excreted in human milk. Due to the potential risk of articular damage, Ciprofloxacin should not be used during lactation.
    Pediatric usageView
    Although effective in clinical trials, Ciprofloxacin is not a drug of first choice in pediatric population.
    Overdose effectsView
    Overdose following Ciprofloxacin administration may lead to seizures, hallucinations, confusion, abdominal discomfort, renal and hepatic impairment as well as crystalluria, haematuria, & reversible renal toxicity.
    StorageView
    Keep below 30°C temperature, protected from light & moisture. Keep out of the reach of children.

    Dumaflox

    Ciprofloxacin
    Tablet 500 mg Allopathic Anti-diarrhoeal Antimicrobial drugs

    Indications

    Urinary tract infection

    Indication detailsView
    Ciprofloxacin is indicated for the treatment of Respiratory Tract Infections,Urinary tract infections, Pelvic Inflammatory Diseases, Infectious Diarrhea (Shigella dysenteriae, Vibrio cholera), Typhoid fever, Intra-abdominal infections, Prostatitis, Skin and Soft Tissue Infections, Bone and Joint Infections, Gonorrhea, Neutropenic patients with fever due to bacterial infection, Meningitis, Surgical prophylaxis.
    Therapeutic classView
    4-Quinolone preparations, Anti-diarrhoeal Antimicrobial drugs
    PharmacologyView
    Ciprofloxacin is a synthetic fluoroquinolone. It has bactericidal activity against a wide range of gram-positive and gram-negative organisms. It inhibits bacterial DNA synthesis by binding with the bacterial enzyme-DNA gyrase and topoisomerase IV which are responsible for DNA supercoiling.
    DosageView
    Tablet: Adult:
    • Respiratory Tract Infections: 500 to 750 mg twice daily (7 to 14 days)
    • Urinary tract infections: 250 to 750 mg twice daily (3 to 10 days)
    • Pelvic Inflammatory Diseases: 500 to 750 mg twice daily (14 days)
    • Infectious Diarrhea (Shigella dysenteriae, Vibrio cholera): 500 mg twice daily (1 to 5 days)
    • Typhoid fever: 500 mg twice daily (7 days)
    • Intra-abdominal infections: 500 to 750 mg twice daily (5 to 14 days)
    • Prostatitis: 500 to 750 mg twice daily (2 to 6 weeks)
    • Skin and Soft Tissue Infections: 500 to 750 mg twice daily (7 to 14 days)
    • Bone and Joint Infections: 500 to 750 mg twice daily (max. 3 months)
    • Gonorrhea: 500 mg as a single dose
    • Neutropenic patients with fever due to bacterial infection: 500 to 750 mg twice daily co-administered with appropriate antibacterials.
    • Meningitis: 500 mg as a single dose.
    • Surgical prophylaxis: 500 mg as a single dose, 60 minutes before the procedure.
    Suspension: Pediatric: 10-20 mg/kg (max. 750 mg) twice daily (10 to 21 days). The duration of therapy depends on the type and severity of the infection.

    Extended-release tablet: In uncomplicated urinary tract infection (acute cystitis), the recommended dose of extended-release tablet is 1000 mg tablet once daily for three days.

    For IV infusion:
    • Urinary Tract Infection: Mild to Moderate: 200 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 12 hourly for 7-14 days
    • Lower Respiratory Tract infection: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days
    • Nosocomial Pneumonia: Mild/Moderate/Severe: 400 mg 8 hourly for 10-14 days
    • Skin and Skin Structure: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days
    • Bone and Joint Infection: Mild to Moderate: 400 mg 12 hourly for more than 4-6 weeks; Severe/Complicated: 400 mg 8 hourly for more than 4-6weeks
    • Intraabdominal (Acute abdomen): Complicated: 400 mg 12 hourly for 7-14 days
    • Acute Sinusitis: Mild/Moderate: 400 mg 12 hourly for 10 days
    • Chronic Bacterial Prostatitis: Mild/Moderate: 400 mg 12 hourly for 28 Days.
    AdministrationView
    Instruction for the use of Ciprofloxacin IV infusion-
    • Check the bag for minute leaks by squeezing the inner bag firmly. If leaks are found, or if seal is not intact, discard the solution.
    • Do not use if the solution is cloudy or a precipitate is present.
    • Do not use flexible bags in series connections.
    • Close flow control clamp of administration set.
    • Remove cover from port at bottom of bag.
    • Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated.
    • Suspend bag from hanger.
    • Squeeze and release drip chamber to establish proper fluid level in chamber during infusion of Ciprofloxacin IV infusion.
    • Open flow control clamp to expel air from set.Close clamp.
    • Regulate rate of administration with flow control clamp
    Duration of treatment: The duration of treatment depends upon the severity of infection, clinical response and bacteriological findings. For acute infections the usual treatment period is 5 to 10 days. Generally treatment should be continued for 3 days after the signs and symptoms of the infection have been disappeared.
    Side effectsView
    Side effects include- nausea and other gastrointestinal disturbances, headache, dizziness, joint pain and skin rashes.
    ContraindicationsView
    It is contraindicated in patients who have known hypersensitivity to Ciprofloxacin or other quinolones.
    PrecautionsView
    Patients receiving Ciprofloxacin should be instructed to drink fluids liberally. It should be used with caution in patients with suspected or known CNS disorders such as epilepsy or other factors which predispose to seizures and convulsion. Avoid in patients with known QT prolongation, hypokalemia.
    InteractionsView
    Concurrent administration of Ciprofloxacin should be avoided with Magnesium or Aluminum containing antacids or sucralfate or with other products containing Calcium, Iron or Zinc. These products may be taken two hours after or six hours before Ciprofloxacin. Ciprofloxacin should not be taken concurrently with milk or other dairy products, since absorption of Ciprofloxacin may be significantly reduced. Dietary calcium is a part of a meal, however, does not significantly affect the absorption of Ciprofloxacin.
    Pregnancy & lactationView
    There are no adequate and well-controlled studies in pregnant women. Ciprofloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus and mother. Ciprofloxacin is excreted in human milk. Due to the potential risk of articular damage, Ciprofloxacin should not be used during lactation.
    Pediatric usageView
    Although effective in clinical trials, Ciprofloxacin is not a drug of first choice in pediatric population.
    Overdose effectsView
    Overdose following Ciprofloxacin administration may lead to seizures, hallucinations, confusion, abdominal discomfort, renal and hepatic impairment as well as crystalluria, haematuria, & reversible renal toxicity.
    StorageView
    Keep below 30°C temperature, protected from light & moisture. Keep out of the reach of children.

    Dumaflox

    Ciprofloxacin
    Tablet 750 mg Allopathic Anti-diarrhoeal Antimicrobial drugs

    Indications

    Urinary tract infection

    Indication detailsView
    Ciprofloxacin is indicated for the treatment of Respiratory Tract Infections,Urinary tract infections, Pelvic Inflammatory Diseases, Infectious Diarrhea (Shigella dysenteriae, Vibrio cholera), Typhoid fever, Intra-abdominal infections, Prostatitis, Skin and Soft Tissue Infections, Bone and Joint Infections, Gonorrhea, Neutropenic patients with fever due to bacterial infection, Meningitis, Surgical prophylaxis.
    Therapeutic classView
    4-Quinolone preparations, Anti-diarrhoeal Antimicrobial drugs
    PharmacologyView
    Ciprofloxacin is a synthetic fluoroquinolone. It has bactericidal activity against a wide range of gram-positive and gram-negative organisms. It inhibits bacterial DNA synthesis by binding with the bacterial enzyme-DNA gyrase and topoisomerase IV which are responsible for DNA supercoiling.
    DosageView
    Tablet: Adult:
    • Respiratory Tract Infections: 500 to 750 mg twice daily (7 to 14 days)
    • Urinary tract infections: 250 to 750 mg twice daily (3 to 10 days)
    • Pelvic Inflammatory Diseases: 500 to 750 mg twice daily (14 days)
    • Infectious Diarrhea (Shigella dysenteriae, Vibrio cholera): 500 mg twice daily (1 to 5 days)
    • Typhoid fever: 500 mg twice daily (7 days)
    • Intra-abdominal infections: 500 to 750 mg twice daily (5 to 14 days)
    • Prostatitis: 500 to 750 mg twice daily (2 to 6 weeks)
    • Skin and Soft Tissue Infections: 500 to 750 mg twice daily (7 to 14 days)
    • Bone and Joint Infections: 500 to 750 mg twice daily (max. 3 months)
    • Gonorrhea: 500 mg as a single dose
    • Neutropenic patients with fever due to bacterial infection: 500 to 750 mg twice daily co-administered with appropriate antibacterials.
    • Meningitis: 500 mg as a single dose.
    • Surgical prophylaxis: 500 mg as a single dose, 60 minutes before the procedure.
    Suspension: Pediatric: 10-20 mg/kg (max. 750 mg) twice daily (10 to 21 days). The duration of therapy depends on the type and severity of the infection.

    Extended-release tablet: In uncomplicated urinary tract infection (acute cystitis), the recommended dose of extended-release tablet is 1000 mg tablet once daily for three days.

    For IV infusion:
    • Urinary Tract Infection: Mild to Moderate: 200 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 12 hourly for 7-14 days
    • Lower Respiratory Tract infection: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days
    • Nosocomial Pneumonia: Mild/Moderate/Severe: 400 mg 8 hourly for 10-14 days
    • Skin and Skin Structure: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days
    • Bone and Joint Infection: Mild to Moderate: 400 mg 12 hourly for more than 4-6 weeks; Severe/Complicated: 400 mg 8 hourly for more than 4-6weeks
    • Intraabdominal (Acute abdomen): Complicated: 400 mg 12 hourly for 7-14 days
    • Acute Sinusitis: Mild/Moderate: 400 mg 12 hourly for 10 days
    • Chronic Bacterial Prostatitis: Mild/Moderate: 400 mg 12 hourly for 28 Days.
    AdministrationView
    Instruction for the use of Ciprofloxacin IV infusion-
    • Check the bag for minute leaks by squeezing the inner bag firmly. If leaks are found, or if seal is not intact, discard the solution.
    • Do not use if the solution is cloudy or a precipitate is present.
    • Do not use flexible bags in series connections.
    • Close flow control clamp of administration set.
    • Remove cover from port at bottom of bag.
    • Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated.
    • Suspend bag from hanger.
    • Squeeze and release drip chamber to establish proper fluid level in chamber during infusion of Ciprofloxacin IV infusion.
    • Open flow control clamp to expel air from set.Close clamp.
    • Regulate rate of administration with flow control clamp
    Duration of treatment: The duration of treatment depends upon the severity of infection, clinical response and bacteriological findings. For acute infections the usual treatment period is 5 to 10 days. Generally treatment should be continued for 3 days after the signs and symptoms of the infection have been disappeared.
    Side effectsView
    Side effects include- nausea and other gastrointestinal disturbances, headache, dizziness, joint pain and skin rashes.
    ContraindicationsView
    It is contraindicated in patients who have known hypersensitivity to Ciprofloxacin or other quinolones.
    PrecautionsView
    Patients receiving Ciprofloxacin should be instructed to drink fluids liberally. It should be used with caution in patients with suspected or known CNS disorders such as epilepsy or other factors which predispose to seizures and convulsion. Avoid in patients with known QT prolongation, hypokalemia.
    InteractionsView
    Concurrent administration of Ciprofloxacin should be avoided with Magnesium or Aluminum containing antacids or sucralfate or with other products containing Calcium, Iron or Zinc. These products may be taken two hours after or six hours before Ciprofloxacin. Ciprofloxacin should not be taken concurrently with milk or other dairy products, since absorption of Ciprofloxacin may be significantly reduced. Dietary calcium is a part of a meal, however, does not significantly affect the absorption of Ciprofloxacin.
    Pregnancy & lactationView
    There are no adequate and well-controlled studies in pregnant women. Ciprofloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus and mother. Ciprofloxacin is excreted in human milk. Due to the potential risk of articular damage, Ciprofloxacin should not be used during lactation.
    Pediatric usageView
    Although effective in clinical trials, Ciprofloxacin is not a drug of first choice in pediatric population.
    Overdose effectsView
    Overdose following Ciprofloxacin administration may lead to seizures, hallucinations, confusion, abdominal discomfort, renal and hepatic impairment as well as crystalluria, haematuria, & reversible renal toxicity.
    StorageView
    Keep below 30°C temperature, protected from light & moisture. Keep out of the reach of children.

    Dumaflox

    Ciprofloxacin
    Powder for Suspension 250 mg/5 ml Allopathic Anti-diarrhoeal Antimicrobial drugs

    Indications

    Urinary tract infection

    Indication detailsView
    Ciprofloxacin is indicated for the treatment of Respiratory Tract Infections,Urinary tract infections, Pelvic Inflammatory Diseases, Infectious Diarrhea (Shigella dysenteriae, Vibrio cholera), Typhoid fever, Intra-abdominal infections, Prostatitis, Skin and Soft Tissue Infections, Bone and Joint Infections, Gonorrhea, Neutropenic patients with fever due to bacterial infection, Meningitis, Surgical prophylaxis.
    Therapeutic classView
    4-Quinolone preparations, Anti-diarrhoeal Antimicrobial drugs
    PharmacologyView
    Ciprofloxacin is a synthetic fluoroquinolone. It has bactericidal activity against a wide range of gram-positive and gram-negative organisms. It inhibits bacterial DNA synthesis by binding with the bacterial enzyme-DNA gyrase and topoisomerase IV which are responsible for DNA supercoiling.
    DosageView
    Tablet: Adult:
    • Respiratory Tract Infections: 500 to 750 mg twice daily (7 to 14 days)
    • Urinary tract infections: 250 to 750 mg twice daily (3 to 10 days)
    • Pelvic Inflammatory Diseases: 500 to 750 mg twice daily (14 days)
    • Infectious Diarrhea (Shigella dysenteriae, Vibrio cholera): 500 mg twice daily (1 to 5 days)
    • Typhoid fever: 500 mg twice daily (7 days)
    • Intra-abdominal infections: 500 to 750 mg twice daily (5 to 14 days)
    • Prostatitis: 500 to 750 mg twice daily (2 to 6 weeks)
    • Skin and Soft Tissue Infections: 500 to 750 mg twice daily (7 to 14 days)
    • Bone and Joint Infections: 500 to 750 mg twice daily (max. 3 months)
    • Gonorrhea: 500 mg as a single dose
    • Neutropenic patients with fever due to bacterial infection: 500 to 750 mg twice daily co-administered with appropriate antibacterials.
    • Meningitis: 500 mg as a single dose.
    • Surgical prophylaxis: 500 mg as a single dose, 60 minutes before the procedure.
    Suspension: Pediatric: 10-20 mg/kg (max. 750 mg) twice daily (10 to 21 days). The duration of therapy depends on the type and severity of the infection.

    Extended-release tablet: In uncomplicated urinary tract infection (acute cystitis), the recommended dose of extended-release tablet is 1000 mg tablet once daily for three days.

    For IV infusion:
    • Urinary Tract Infection: Mild to Moderate: 200 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 12 hourly for 7-14 days
    • Lower Respiratory Tract infection: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days
    • Nosocomial Pneumonia: Mild/Moderate/Severe: 400 mg 8 hourly for 10-14 days
    • Skin and Skin Structure: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days
    • Bone and Joint Infection: Mild to Moderate: 400 mg 12 hourly for more than 4-6 weeks; Severe/Complicated: 400 mg 8 hourly for more than 4-6weeks
    • Intraabdominal (Acute abdomen): Complicated: 400 mg 12 hourly for 7-14 days
    • Acute Sinusitis: Mild/Moderate: 400 mg 12 hourly for 10 days
    • Chronic Bacterial Prostatitis: Mild/Moderate: 400 mg 12 hourly for 28 Days.
    AdministrationView
    Instruction for the use of Ciprofloxacin IV infusion-
    • Check the bag for minute leaks by squeezing the inner bag firmly. If leaks are found, or if seal is not intact, discard the solution.
    • Do not use if the solution is cloudy or a precipitate is present.
    • Do not use flexible bags in series connections.
    • Close flow control clamp of administration set.
    • Remove cover from port at bottom of bag.
    • Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated.
    • Suspend bag from hanger.
    • Squeeze and release drip chamber to establish proper fluid level in chamber during infusion of Ciprofloxacin IV infusion.
    • Open flow control clamp to expel air from set.Close clamp.
    • Regulate rate of administration with flow control clamp
    Duration of treatment: The duration of treatment depends upon the severity of infection, clinical response and bacteriological findings. For acute infections the usual treatment period is 5 to 10 days. Generally treatment should be continued for 3 days after the signs and symptoms of the infection have been disappeared.
    Side effectsView
    Side effects include- nausea and other gastrointestinal disturbances, headache, dizziness, joint pain and skin rashes.
    ContraindicationsView
    It is contraindicated in patients who have known hypersensitivity to Ciprofloxacin or other quinolones.
    PrecautionsView
    Patients receiving Ciprofloxacin should be instructed to drink fluids liberally. It should be used with caution in patients with suspected or known CNS disorders such as epilepsy or other factors which predispose to seizures and convulsion. Avoid in patients with known QT prolongation, hypokalemia.
    InteractionsView
    Concurrent administration of Ciprofloxacin should be avoided with Magnesium or Aluminum containing antacids or sucralfate or with other products containing Calcium, Iron or Zinc. These products may be taken two hours after or six hours before Ciprofloxacin. Ciprofloxacin should not be taken concurrently with milk or other dairy products, since absorption of Ciprofloxacin may be significantly reduced. Dietary calcium is a part of a meal, however, does not significantly affect the absorption of Ciprofloxacin.
    Pregnancy & lactationView
    There are no adequate and well-controlled studies in pregnant women. Ciprofloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus and mother. Ciprofloxacin is excreted in human milk. Due to the potential risk of articular damage, Ciprofloxacin should not be used during lactation.
    Pediatric usageView
    Although effective in clinical trials, Ciprofloxacin is not a drug of first choice in pediatric population.
    Overdose effectsView
    Overdose following Ciprofloxacin administration may lead to seizures, hallucinations, confusion, abdominal discomfort, renal and hepatic impairment as well as crystalluria, haematuria, & reversible renal toxicity.
    StorageView
    Keep below 30°C temperature, protected from light & moisture. Keep out of the reach of children.

    Dumax

    Dapoxetine Hydrochloride
    Tablet 30 mg Allopathic Drugs for Erectile Dysfunction

    Indications

    Premature ejaculation

    Indication detailsView
    Indicated for the treatment of premature ejaculation (PE) in men 18 to 64 years of age, who have all of the following:
    • Persistent or recurrent ejaculation with minimal sexual stimulation before, on or shortly after penetration and before the patient wishes.
    • Marked personal distress or interpersonal difficulty as a consequence of PE and poor control over ejaculation.
    Therapeutic classView
    Drugs for Erectile Dysfunction
    PharmacologyView
    The mechanism of action is thought to be related to inhibition of neuronal reuptake of serotonin and subsequent potentiation of serotonin activity. The central ejaculatory neural circuit comprises spinal and cerebral areas that form a highly interconnected network. The sympathetic, parasympathetic, and somatic spinal centers, under the influence of sensory genital and cerebral stimuli integrated and processed at the spinal cord level, act in synergy to command physiologic events occurring during ejaculation. Experimental evidence indicates that serotonin (5-HT), throughout brain descending pathways, exerts an inhibitory role on ejaculation. To date, three 5-HT receptor subtypes 5-HT(1A), 5-HT(1B), and 5-HT(2C) have been postulated to mediate 5-HT's modulating activity on ejaculation.
    DosageView
    Adult (18 to 64 years of age): The recommended starting dose for all patients is 30 mg, taken as needed approximately 1 to 3 hours prior to sexual activity. If the effect of 30 mg is insufficient and the side effects are acceptable, the dose may be increased to the maximum recommended dose of 60 mg. The maximum recommended dosing frequency is one dose every 24 hours.
    Side effectsView
    Dizziness, Headache, Somnolence, Tremor, Blurred vision, Tinnitus, Sinus congestion, Nausea, Diarrhea, Abdominal pain, Dry mouth, Fatigue, Insomnia, Hypertension.
    ContraindicationsView
    • Patients with known hypersensitivity to Dapoxetine Hydrochloride.
    • Patients with significant pathological cardiac conditions such as heart failure (NYHA class II-IV), conduction abnormalities (second or third degree AV block or sick sinus syndrome) not treated with a permanent pacemaker, significant ischemic heart disease of significant valvular disease.
    • Concomitant treatment with monoamine oxidase inhibitors (MAOIs), thioridazine. Similarly, MAOIs or thioridazine should not be administered within 7 days after Dapoxetine has been discontinued.
    • Concomitant treatment with serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs) or other medicinal/herbal products with serotonergic effects or within 14 days of discontinuing treatment with these medicinal/herbal products.
    PrecautionsView
    Patient with bleeding disorders, epilepsy, susceptibility to angle-closure glaucoma or raised intraocular pressure. Not intended for use in women. Known CYP2D6 poor metabolisers.
    InteractionsView
    CNS active medicinal products: The use of Dapoxetine in combination with CNS active medicinal products has not been systematically evaluated in patients with premature ejaculation. Consequently, caution is advised if the concomitant administration of Dapoxetine and such medicinal products is required.

    PDE5 inhibitors: Tadalafil did not affect the pharmacokinetics of Dapoxetine. Sildenafil caused slight changes in Dapoxetine pharmacokinetics, which are not expected to be clinically significant. However, Dapoxetine should be prescribed with caution in patients who use PDE5 inhibitors due to possible reduced orthostatic tolerance.

    Tamsulosin: Concomitant administration of single or multiple doses of 30 mg or 60 mg Dapoxetine to patients receiving daily doses of Tamsulosin did not result in changes in the pharmacokinetics of Tamsulosin. However, Dapoxetine should be prescribed with caution in patients who use alpha adrenergic receptor antagonists due to possible reduced orthostatic tolerance.

    Warfarin: There are no data evaluating the effect of chronic use of Warfarin with Dapoxetine; therefore, caution is advised when Dapoxetine is used in patients taking Warfarin chronically.

    Ethanol: Concomitant use of alcohol and Dapoxetine could increase the chance or severity of adverse reactions such as dizziness, drowsiness, slow reflexes, or altered judgment. Combining alcohol with Dapoxetine may increase these alcohol-related effects and may also enhance neurocardiogenic adverse events such as syncope, thereby increasing the risk of accidental injury; therefore, patients should be advised to avoid alcohol while taking Dapoxetine.
    Pregnancy & lactationView
    Dapoxetine is not indicated for use by women. It is not known either dapoxetine or its metabolites are excreted through human breast milk.
    Overdose effectsView
    There were no unexpected adverse events in a clinical pharmacology study of Dapoxetine with daily doses up to 240 mg. In general, symptoms of overdose with SSRIs include serotonin-mediated adverse reactions such as somnolence, gastrointestinal disturbances such as nausea and vomiting, tachycardia, tremor, agitation and dizziness. In cases of overdose, standard supportive measures should be adopted as required.
    StorageView
    Store below 30°C. Protect from light and moisture. Keep out of reach of children